Reni Benjamin

H.C. Wainwright Reiterates Buy On CTI Biopharma Following Completion Of Phase 3 Trial

In a research report released Tuesday, HC Wainwright analyst Reni Benjamin reiterated a Buy rating on CTI BioPharma Corp (CTIC) with a price target of $6.00 following the completion of …

Editor Ben Weinberg — July 2, 2014, 8:37 AM EDT

Agenus Represents An Undervalued Player In The Immuno-Oncology Space, Says H.C. Wainwright

In a research note issued this morning, H.C.

Ben Mahaney, Editor — June 27, 2014, 8:40 AM EDT

H.C. Wainwright Assumes Buy On OXiGENE, Reduces Price Target To $6

In a research note released today, H.C.

Editor Ben Weinberg — June 26, 2014, 9:10 AM EDT

H.C. Wainwright Initiates Buy On Cesca Therapeutics; Sets $5 Price Target

In a research noted released today, H.C.

Editor Ben Weinberg — June 26, 2014, 8:28 AM EDT

H.C. Wainwright Reiterates Buy On OncoSec Following YTD Results

In a research note issued this morning, H.C.

Ben Mahaney, Editor — June 19, 2014, 7:37 AM EDT

H.C. Wainwright Keeps ‘Buy’ On Ariad Following $200 Million Offering

In a research note issued today, H.C.

Ben Mahaney, Editor — June 17, 2014, 5:16 PM EDT

CTI BioPharma Reiterated With A Buy At H.C. Wainwright

In a research note issued this morning, H.C.

Ben Mahaney, Editor — June 13, 2014, 2:27 PM EDT

Celsion Corp. Reiterated With A Buy At H.C.Wainwright

H.C.

Ben Mahaney, Editor — June 11, 2014, 11:38 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts